Evidence map›Paper›PMID 28319106›Full record

SynthesisNutrition & diabetes2017

A systematic review on the impact of diabetes mellitus on the ocular surface.

K Co Shih, K S-L Lam, L Tong

3 registry-linked trialsAbstract readSystematic Review
In one paragraph

Synthesis in Nutrition & diabetes, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 102 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
102citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04980144 naunknown statusnot on this mapstarted 2023, after this paper: background citation

Impact of Diquafosol Ophthalmic Solution on Tear Film and Dry Eye Symptom in Type 2 Diabetic Dry Eye: A Four-week Randomized Control, Single Masked Pilot Study.

TypeinterventionalSponsorHe Eye HospitalRan2023 to 2023Enrolled101ConditionsDiabetic Eye ProblemsArms3% Diquafosol tetrasodium, 0.1% hyaluronate
NCT05193331 naunknown statusnot on this mapstarted 2023, after this paper: background citation

3% Diquafosol Topical Ophthalmic Solution in Diabetic Patients With Dry Eye

TypeinterventionalSponsorHe Eye HospitalRan2023 to 2023Enrolled70ConditionsDiabetic Eye ProblemsArms3% Diquafosol tetrasodium
NCT05682547 nacompletednot on this mapstarted 2022, after this paper: background citation

A Single Center, Randomized, Controlled Trial Comparing the Clinical Efficacy of 3% Diquafosol Tetrasodium and 0.1 % Hyaluronic Acid 0.1% in Diabetic Patients With Dry Eye Disease

TypeinterventionalSponsorHe Eye HospitalRan2022 to 2023Enrolled99ConditionsDiabetic Eye ProblemsArms3% Diquafosol tetrasodium, 0.1% hyaluronate
3 · Its place in the literature

Who cites it

102 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Diabetic keratopathy and nuclear proteins (Review).Molecular medicine reports · 2026
    Review
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Assessment of insulin-degrading enzyme inhibitor for the treatment of corneal erosion in a rat model.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2025
    Article

42 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

K Co ShihDepartment of Ophthalmology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China.
K S-L LamResearch Center of Heart, Brain, Hormone and Healthy Aging, The University of Hong Kong, Hong Kong.
L TongSingapore Eye Research Institute, National Eye Centre, Singapore.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Diabetes mellitus is associated with extensive morbidity and mortality in any human community. It is well understood that the burden of diabetes is attributed to chronic progressive damage in major end-organs, but it is underappreciated that the most superficial and transparent organ affected by diabetes is the cornea. Different corneal components (epithelium, nerves, immune cells and endothelium) underpin specific systemic complications of diabetes. Just as diabetic retinopathy is a marker of more generalized microvascular disease, corneal nerve changes can predict peripheral and autonomic neuropathy, providing a window of opportunity for early treatment. In addition, alterations of immune cells in corneas suggest an inflammatory component in diabetic complications. Furthermore, impaired corneal epithelial wound healing may also imply more widespread disease. The non-invasiveness and improvement in imaging technology facilitates the emergence of new screening tools. Systemic control of diabetes can improve ocular surface health, possibly aided by anti-inflammatory and vasoprotective agents.

Indexed as

Corneal DiseasesDiabetes Mellitus, Type 1Diabetes Mellitus, Type 2Epithelium, CornealHumans

Identifiers

PMID28319106
PMCPMC5380897

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.